FWBI

First Wave BioPharma, Inc. (FWBI) | Rumor.io

First Wave BioPharma

FWBI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about FWBI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 15

The latiglutenase from immunogenX is a promising treatment for celiacs and gluten allergies, and First Wave BioPharma, Inc. is working to bring it to market.
The company is doing well, with a strong product pipeline and a good track record, which has led to short selling and speculation about its future.
There is a large amount of short interest in the stock, with over 330% coverage, making it an attractive opportunity for buyers.

Generated by AI

Sentiment

Of the messages about FWBI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.46% +84.76
Bearish	—	—	—	11.54% -84.76

Bullish· Mar 14

$FWBI is expected to receive $10m in funding to bring its product to market, with no dilution for existing shareholders.
The company's low float and recent volume of over 700k shares make it a potentially explosive stock.
$FWBI is a leader in the development of an oral biotherapeutic for Celiac disease, a huge market with a phase 3 ready product.

Bearish· Mar 14

The company's management lacks focus, leading to burning cash and a potential dilutive death spiral.
The CEO may use phantom shares to artificially lower the stock price, potentially driving it to penny land.
The company's speculative deal and significant dilution have eroded its value, making it unlikely to be worth $40 or more.

Generated by AI

Topics

Of the messages about FWBI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Sep 14

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi, with potential milestone payments of up to $46M and $235M.
The licensing agreement includes a modest upfront payment, backend milestone payments, and single-digit royalties on net sales, with Sanofi retaining a right of first refusal to reacquire Capeserod.
Capeserod has shown potential applications for several gastrointestinal disorders in multibillion-dollar markets, with Sanofi's research and AI-empowered analyses supporting its repurposing for these indications.

Technical Analysis· Jun 14

$FWBI trend traded in after-hours, with a potential retest of a daily support level.
$FWBI had low average volume of 92k, which may have contributed to its poor performance.
$FWBI was a day 1 gapper that didn't meet expectations, serving as a reminder to treat system trades as system trades.

Generated by AI

Community

Of the messages about FWBI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	7.5%
Newcomers	—	—	—	92.5%

Regulars· Sep 5

The $FWBI stock price has been experiencing a parabolic continuation, with a strong bid and potential for further growth.
The company has a low priced NASDAQ stock with a small market capitalization and a low short interest of 0.49%.
$FWBI has been granted a US patent for "METHODS OF TREATMENT (FOR CORONAVIRUS COVID-19)" and is participating in the H.C. Wainwright 25th Annual Global Investment Conference.

Newcomers· Sep 5

Many newcomers are shorting FWBI, citing its high volatility and limited liquidity as concerns.
Some users are drawing comparisons between FWBI and other companies, such as PBTS, GTBP, and TTOO, in terms of their market performance and potential.
The patent news and potential treatment for COVID-19 are being highlighted as significant factors in FWBI's recent price increase.

Generated by AI

Also Discussed

Investors talking about FWBI also mention

#	Name	Attention
1	NextPlay Technologies Inc.NXTP	0%0
2	ZVSA - ZyVersa Therapeutics, Inc.	——
3	Cingulate Inc.CING	0%new
4	Revelation Biosciences Inc.REVB	0%0
5	PaxMedica Inc.PXMD	0%0
6	United Maritime CorporationUSEA	0%0
7	NRBO - NeuroBo Pharmaceuticals, Inc.	——
8	Avenue Therapeutics Inc.ATXI	0%new
9	Digital Brands Group, Inc. Common StockDBGI	0%0
10	Performance Shipping Inc.PSHG	0%0